Therma Bright Inc. Makes Significant Strides in Healthcare Innovation with
Therma Bright Inc. (OTC: TBRIF), a growing player in the healthcare industry, is making significant progress with its diverse portfolio of innovative medical devices and diagnostic solutions. The company’s flagship product, the Venowave VW5, is designed to enhance blood circulation and targets the deep vein thrombosis (DVT) treatment market, which is expected to grow to $1.62 billion by 2032. Therma Bright’s ambitions extend beyond DVT, encompassing cutting-edge technology to address various health challenges, from respiratory disease management to pain relief.
The Venowave VW5, an FDA-approved circulation booster, has shown promise in preventing DVT, a condition affecting up to 900,000 people in the U.S. annually. The device’s potential has been recognized by the healthcare industry, with Therma Bright securing a nationwide U.S. distribution partner in August 2024. This partnership could lead to inventory acquisitions worth $2.38 million, subject to the success of an initial sales program.
Further bolstering the Venowave VW5’s credibility, Therma Bright received a permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services’ Centers for Medicare and Medicaid Services (CMS). This designation is expected to enhance the product’s market position and could be instrumental in Therma Bright’s efforts to become a leader in the DVT treatment market.
In the realm of stroke treatment, Therma Bright has invested in Inretio, the developer of the Preva® clot-retrieval device. This technology, which recently completed its third successful human trial, aims to revolutionize ischemic stroke treatment by improving effectiveness and reducing complications during thrombectomy procedures. With over 690,000 ischemic stroke patients in the U.S. each year, the Preva® device could significantly impact patient outcomes in a market projected to reach $16.14 billion by 2030.
Therma Bright is also expanding its presence in the respiratory health sector through its stake in InStatin, a company developing inhaled statin therapies for conditions such as asthma and chronic obstructive pulmonary disease (COPD). The COPD market alone is estimated to be worth over $16 billion annually, presenting a substantial growth opportunity for Therma Bright as InStatin’s therapies progress through pre-clinical trials.
The company’s innovation pipeline extends to digital health solutions, including a Digital Cough Test app developed in partnership with AI4LYF. This app uses artificial intelligence to monitor respiratory diseases based on cough sounds, potentially offering a novel approach to remote patient monitoring and treatment.
Therma Bright’s diverse portfolio also includes products like the Benepod™ for pain relief, AcuVid™ COVID-19 Rapid Antigen Test Solution, InterceptCS™ for cold sore prevention, and TherOZap™ for insect bite relief, demonstrating the company’s commitment to addressing a wide range of healthcare needs.
The company’s recent achievements and strategic investments position it to potentially capture significant market share across
